Exenatide Reduces Urinary Transforming Growth Factor-β1 and Type IV Collagen Excretion in Patients with Type 2 Diabetes and Microalbuminuria

Kidney and Blood Pressure Research

Hu C.²  Lu W.²  Zhang H.²  Zhang X.¹ 

[1] Endocrinology and $$

关键词: Type IV collagen;    Exenatide;    Diabetic nephropathy;    Urinary biomarkers;    Transforming growth factor-β1;   

DOI  :  10.1159/000337929

来源: S Karger AG

【 摘 要 】

Aims: It was reported that exenatide ameliorated renal injury in diabetic rats. The present study was carried out to evaluate the effect of exenatide on 24-hour urinary albumin, urinary transforming growth factor-β₁ (TGF-β₁) and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Methods: 31 type 2 diabetic patients with microalbuminuria were randomly allocated to receive exenatide (group Exe, n = 13) or glimepiride treatment (group Glm, n = 18) for 16 weeks. Body mass index (BMI), fasting plasma glucose, 2-hour postprandial plasma glucose, glycated hemoglobin A_1c, systolic blood pressure, diastolic blood pressure, 24-hour urinary albumin, urinary TGF-β₁ and type IV collagen concentration were analyzed between the two treatment groups. 20 age- and BMI-matched healthy subjects were chosen as the normal control group (group NC, n = 20). Results: After 16 weeks of treatment, 24-hour urinary albumin, urinary TGF-β₁ and type IV collagen in group Exe were significantly lower than those of group Glm (p < 0.01), while glycemic control had no statistical difference between the two groups. Conclusions: Our results indicate that exenatide reduces urinary TGF-β₁ and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria, which may be partly contributory to its directly renoprotective role.

【 授权许可】

Unknown